Nitric oxide inhalation - AIT

Drug Profile

Nitric oxide inhalation - AIT

Alternative Names: AIT-CF; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer AIT; Schneider Childrens Medical Center of Israel; University of British Columbia
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cystic fibrosis; Respiratory syncytial virus infections
  • Phase I Pneumonia; Respiratory tract infections
  • Research Asthma

Most Recent Events

  • 20 Feb 2017 AIT plans a phase III trial for Bronchiolitis (NCT03053388)
  • 27 Apr 2016 AIT completes a phase II clinical trial in Respiratory syncytial virus infections (in infants) in Israel (Inhalation) (NCT01768884)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top